Methods of treating amyloidosis with humanized anti-beta-amyloid antibodies

• US 8,246,954 B2
• Filed: 07/23/2009
• Issued: 08/21/2012
• Est. Priority Date: 07/14/2006
• Status: Active Grant

• Current Assignee: AC Immune SA, Genentech, Inc. (Roche Holding AG)
• Original Assignee: AC Immune SA, Genentech, Inc. (Roche Holding AG)
• Inventors: Pfeifer, Andrea, Pihlgren, Maria, Muhs, Andreas, Watts, Ryan
• Primary Examiner(s): Bunner, Bridget E
• Assistant Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US12/460,747
• Publication Number:
  US 20100080800A1
• Time in Patent Office: 1,125 Days
• Field of Search: None
• US Class Current: 424/133.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/28 against receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/56 variable (Fv) region, i.e. VH and/or VL
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer'"'"'s disease.

Claims

1. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) a Heavy Chain Variable Region (HCVR) CDR1 having the amino acid sequence of SEQ ID NO;

1,

(iii) an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2,

(iv) an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, and

(v) a Light Chain Variable Region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, wherein the LCVR comprises an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution; and

wherein at least one of the effects of the disease or disorder associated with amyloid plaque formation is treated or alleviated.

3. The method of claim 1 or 2, wherein the disease or disorder is Alzheimer'"'"'s Disease.

4. The method of claim 1 or 2, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

21. The method of claim 1, 2, 5, 6, 11 or 12, wherein said antibody or fragment thereof comprises the humanized light chain of SEQ ID NO:

13.

22. The method of claim 1, 2, 5, 6, 11 or 12, wherein said antibody or fragment thereof comprises the humanized heavy chain of SEQ ID NO:

16.

23. The method of claim 22, wherein the C-terminal Lys of the heavy chain constant region has been removed.

24. The method according to claim 1, 2, 5, 6, 11 or 12, wherein said antibody or fragment thereof is of the IgG4 isotype.

25. The method of claim 1, 5, or 11, wherein said antibody or fragment thereof binds to a beta-amyloid monomer with a binding affinity of at least about 1×

10<sup>−

8</sup> M to at least about 1×

10<sup>−

11</sup> M.

26. The method of claim 1, 5, or 11, wherein said antibody or fragment thereof binds to a beta-amyloid fiber, fibril or filament with a binding affinity of at least about 1×

10<sup>−

9</sup> M to at least about 1×

10<sup>−

10</sup> M.

2. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering a composition to an animal or a human in need thereof, wherein said composition comprises a therapeutically effective amount of an antibody or fragment thereof capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

(iii) an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2,

(iv) an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, and

(v) a Light Chain Variable Region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, wherein the LCVR comprises an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution in a therapeutically effective amount.

9. The method of claim 2 or 6, wherein the framework regions comprise human germline VK sequences of Kabat subgroup VKII.

10. The method of claim 2 or 6, wherein the framework regions comprise human germline VH sequences of Kabat subgroup VHIII.

5. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) a Light Chain Variable Region (LCVR) CDR1 having the amino acid sequence of SEQ ID NO;

4,

(iii) an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution,

(iv) an LCVR CDR3 having the amino acid sequence of SEQ ID NO;

6, and

(v) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15; and

wherein at least one of the effects of the disease or disorder associated with amyloid plaque formation is treated or alleviated.

7. The method of claim 5 or 6, wherein the disease or disorder is Alzheimer'"'"'s Disease.

8. The method of claim 5 or 6, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

6. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof a composition comprising a therapeutically effective amount of an antibody or fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) a Light Chain Variable Region (LCVR) CDR1 having the amino acid sequence of SEQ ID NO;

4,

(iii) an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution,

(iv) an LCVR CDR3 having the amino acid sequence of SEQ ID NO;

6, and

(v) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15.

11. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions;

(ii) an HCVR comprising an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2, and

an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, wherein said HCVR comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15; and

(iii) an LCVR comprising an LCVR CDR1 having the amino acid sequence of SEQ ID NO;

4,

an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution, and

an LCVR CDR3 having the amino acid sequence of SEQ ID NO;

6, wherein said LCVR comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12; and

wherein at least one of the effects of the disease or disorder associated with amyloid plaque formation is treated or alleviated.

13. The method of claim 11 or 12, wherein the disease or disorder is Alzheimer'"'"'s Disease.

14. The method of claim 11 or 12, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

15. The method according to claim 11 or 12, wherein the HCVR has the amino acid sequence of SEQ ID NO:

15.

16. The method according to claim 11 or 12, wherein the LCVR has the amino acid sequence of SEQ ID NO:

12.

17. The method of claim 11 or 12, wherein the CDR2 of the LCVR has the amino acid sequence of SEQ ID NO:

5, SEQ ID NO;

40, or SEQ ID NO;

41.

18. The method of claim 11 or 12, wherein the CDR2 of the LCVR has the amino acid sequence of SEQ ID NO:

5.

19. The method of claim 11 or 12, wherein the amino acid substitution is a conservative amino acid substitution.

20. The method of claim 11 or 12, wherein said antibody or fragment thereof comprises the humanized light chain of SEQ ID NO:

13 and the humanized heavy chain of SEQ ID NO;

16.

12. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof a composition comprising a therapeutically effective amount of an antibody or fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions;

(ii) an HCVR comprising an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2, and

an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, wherein said HCVR comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15; and

(iii) an LCVR comprising an LCVR CDR1 having the amino acid sequence of SEQ ID NO;

4,

an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution, and

an LCVR CDR3 having the amino acid sequence of SEQ ID NO;

6, wherein said LCVR comprises an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12 .

27. A method for the preparation of a composition for use in treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, comprising formulating an antibody or a fragment thereof in a pharmaceutically acceptable form, wherein said antibody or fragment thereof is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

(iii) an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2,

(iv) an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, and

(v) a Light Chain Variable Region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, wherein the LCVR comprises an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution.

28. A method for the preparation of a composition for use in treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, comprising formulating an antibody or a fragment thereof in a pharmaceutically acceptable form, wherein said antibody or fragment thereof comprises:

(i) an HCVR having the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR having the amino acid sequence of SEQ ID NO;

12.

29. A method for disaggregating preformed beta-amyloid fibers, comprising interacting an antibody or fragment thereof with preformed beta-amyloid fibers, wherein said antibody or fragment thereof is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

(iii) an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2,

(iv) an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, and

(v) a Light Chain Variable Region (LCVR) comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, wherein the LCVR comprises an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution.

30. A method for disaggregating preformed beta-amyloid fibers, comprising interacting an antibody or fragment thereof with preformed beta-amyloid fibers, wherein said antibody or fragment thereof is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR having the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR having the amino acid sequence of SEQ ID NO;

12.

31. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof a therapeutically effective amount of an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises an HCVR having the amino acid sequence of SEQ ID NO:

15.

32. The method of claim 31, wherein the disease or disorder is Alzheimer'"'"'s Disease.

33. The method of claim 31, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

34. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof a therapeutically effective amount of an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises an LCVR having the amino acid sequence of SEQ ID NO:

12.

35. The method of claim 34, wherein the disease or disorder is Alzheimer'"'"'s Disease.

36. The method of claim 34, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

37. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation, said method comprising administering to an animal or a human in need thereof a therapeutically effective amount of an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or a fragment thereof comprises:

(i) an HCVR having the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR having the amino acid sequence of SEQ ID NO;

12.

38. The method of claim 37, wherein the disease or disorder is Alzheimer'"'"'s Disease.

39. The method of claim 37, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, ALS (amyotrophic lateral sclerosis), Adult Onset Diabetes, senile cardiac amyloidosis, endocrine tumors, or macular degeneration.

49. The method of claim 37, 40, or 41, wherein said antibody or fragment thereof is of the IgG4 isotype.

40. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation in the brain, said method comprising administering to an animal or a human in need thereof an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) an HCVR CDR1 having the amino acid sequence of SEQ ID NO;

1,

(iii) an HCVR CDR2 having the amino acid sequence of SEQ ID NO;

2,

(iv) an HCVR CDR3 having the amino acid sequence of SEQ ID NO;

3, and

(v) an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, wherein the LCVR comprises an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution; and

wherein at least one of the effects of the disease or disorder associated with amyloid plaque formation in the brain is treated or alleviated.

42. The method of claim 40 or 41, wherein said antibody or fragment thereof comprises the humanized light chain of SEQ ID NO:

13 and the humanized heavy chain of SEQ ID NO;

16.

43. The method of claim 40 or 41, wherein said antibody or fragment thereof comprises an HCVR comprising the amino acid sequence of SEQ ID NO:

15 and an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

44. The method of claim 40 or 41, wherein the C-terminal Lys of the heavy chain constant region has been removed.

45. The method of claim 40 or 41, wherein the CDR2 of the LCVR has the amino acid sequence of SEQ ID NO:

40 or SEQ ID NO;

41.

46. The method of claim 40 or 41, wherein the CDR2 of the LCVR has the amino acid sequence of SEQ ID NO:

5.

47. The method of claim 40 or 41, wherein the disease or disorder is Alzheimer'"'"'s Disease.

48. The method of claim 40 or 41, wherein the disease or disorder is Lewy body dementia, Down'"'"'s syndrome, hereditary cerebral hemorrhage with amyloidosis (Dutch type), the Guam Parkinson-Dementia complex, progressive supranuclear palsy, multiple sclerosis, Creutzfeld Jacob disease, Parkinson'"'"'s disease, HIV-related dementia, or ALS (amyotrophic lateral sclerosis).

41. A method for treating or alleviating the effects of a disease or disorder associated with amyloid plaque formation in the brain, said method comprising administering to an animal or a human in need thereof an antibody or a fragment thereof capable of specifically binding beta-amyloid peptide, wherein said antibody or fragment thereof comprises:

(i) human- or primate-derived framework regions,

(ii) an LCVR CDR1 having the amino acid sequence of SEQ ID NO;

4,

(iii) an LCVR CDR2 having the amino acid sequence of SEQ ID NO;

5 or the amino acid sequence of SEQ ID NO;

5 with one amino acid substitution,

(iv) an LCVR CDR3 having the amino acid sequence of SEQ ID NO;

6, and

(v) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15; and

wherein at least one of the effects of the disease or disorder associated with amyloid plaque formation in the brain is treated or alleviated.

50. A method for retaining or increasing cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15, or

(ii) an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, or

(iii) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12.

51. A method for retaining or increasing cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15, or

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12 or

(iii) an HCVR comprising the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

52. A method for retaining or increasing cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

53. A method for restoring the cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15, or

(ii) an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, or

(iii) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12.

54. A method for restoring the cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15, or

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12 or

(iii) an HCVR comprising the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

55. A method for restoring the cognitive memory capacity of an animal or a human suffering from memory impairment associated with a disease or disorder associated with brain amyloid plaque formation by administering to the animal or the human, a pharmaceutical composition comprising an antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

56. A method of protecting neurons from beta-amyloid induced neuron degradation comprising treating neurons with an effective amount of a humanized antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said humanized antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15 or an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15, or

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12 or an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, or

(iii) an HCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising an amino acid sequence that is at least 98% identical to the amino acid sequence of SEQ ID NO;

12, or

(iv) an HCVR comprising the amino acid sequence of SEQ ID NO;

15 and an LCVR comprising the amino acid sequence of SEQ ID NO;

12.

57. A method of protecting neurons from beta-amyloid induced neuron degradation comprising treating neurons with an effective amount of a humanized antibody or a fragment thereof which is capable of specifically binding beta-amyloid peptide, and wherein said humanized antibody or fragment thereof comprises:

(i) an HCVR comprising the amino acid sequence of SEQ ID NO;

15, and

(ii) an LCVR comprising the amino acid sequence of SEQ ID NO;

12.